Our Guest Outcomes for Treating PTSD
Our psychedelic retreats have gathered years of data to validate the efficacy of our psilocybin retreat model in treating PTSD
By MycoMeditations
What We Have Learned About Treating PTSD with Psilocybin
- MycoMeditations results are comparable to the MAPS PBC Phase 3 trial outcomes. MAPS PBC data, utilizing the CAPS-5 scale, showed the baseline score of 44.0 fell to 19.6 (-55.5%) after 18 weeks. At three months post-retreat, MycoMeditations data, utilizing the PCL-5, showed a 52.7% reduction in symptoms between baseline (43.0) and three months post retreat (20.4). This is largely sustained at six months post-retreat with 48.8% reduction in symptoms, and one year post-retreat with 46.1%.
- MycoMeditations survey reveals one of the first samples of long-term data revealing efficacy for psilocybin-assisted therapy in assisting with PTSD.
- Clinically significant improvements in PTSD maintained one year following retreat.
- Data supports the need for tailored dosing on numerous physical and mental factors rather than standardized dosing based on bodyweight.
- Psilocybin in group therapeutic retreat settings may be a viable treatment for PTSD when supported with individual therapy.
MycoMeditations guest outcome data for treating Post-Traumatic Stress Disorder with psilocybin shows similar results to the Multidisciplinary Association for Psychedelic Studies (MAPS) clinical research trails utilizing MDMA to treat PTSD when comparing results three months after the therapeutic sessions.
While there is significant data showing MDMA's effectiveness in treating Post-Traumatic Stress Disorder, clinical trials examining the effects of psilocybin on PTSD are limited in number. MycoMeditations surveys reveal first-of-its-kind outcomes in the fight against PTSD with psilocybin.
Retreat outcomes remained clinically significant one year after the retreat experience, indicating effectiveness in the MycoMeditations psilocybin-assisted retreat model in treating PTSD. Few psilocybin clinical trials examine outcomes this far from treatment, which advocates for the long-term efficacy of psilocybin in general.
MycoMeditations dosing protocols take into account numerous factors when determining the ideal psilocybin dose for a client. The optimal dose for each person varies significantly, and the MycoMeditations protocol realizes the need for a tailored approach to dosing in order to maximize benefits.
This data also emphasizes the utility of group psychedelic-assisted therapy, as MycoMeditations retreats are group experiences with up to 12 people assisted by therapists, with a typical facilitator-to-client ratio of at least 1:1.5, team to guests.
Population: Real-World Clients
MycoMeditations clients involved in this survey, while seeking therapeutic outcomes for PTSD, do frequently suffer from comorbid conditions such as various forms of depression, anxiety, and/or alcohol use disorder (AUD) or other forms of addiction, among others.
This population is a more accurate representation of real-world sufferers in need of therapeutic intervention than is otherwise found in the participant cohorts of clinical trials, in which such comorbidities are often screened out.
Preparation, Dosing, and Integration Protocols
The survey, which was optional to participate in, was completed by clients enrolling in the seven-day psilocybin-assisted retreat program at MycoMeditations, where they received preparation for their psilocybin sessions, three dosing sessions spaced on alternating days, and group integration on the days between each dosing session. After the retreats had concluded, clients were also encouraged to participate in two group integration sessions via Zoom.
Clients were administered dried Psilocybe cubensis, which is cultivated on-site and encapsulated into 0.5g capsules. MycoMeditations’ dosing regimen is highly standardized for utilizing whole psilocybin mushrooms with an escalating dosing protocol over the course of the three (3) sessions. The dose for Session 1 is virtually identical for all clients, however, the MycoMeditations protocol takes many physical and mental factors into account when determining the ideal dose for Session 2 and Session 3, as a tailored dosing method was found to be most beneficial.
The average dose in dried, encapsulated grams of psilocybin mushrooms from Session 1 has an average SD of 3.63 ± 1.11. Session 2 has an average SD of 6.51 ± 1.55 and Session 3 has an average SD of 8.13 ± 3.25. The total dose over the duration of the retreat has an average SD of 18.27 ± 4.76.
Results for the Treatment of PTSD at MycoMeditations Psilocybin Retreats
The PTSD dataset was examined using the PCL-5 rating scale. A PCL-5 minimum score of 31 (considered moderate levels of PTSD) was selected as inclusion criteria for a baseline response to be included in the dataset. The baseline results included 129 participants.
The baseline dataset, verified by a third-party source, determined that people suffering from moderate to extreme levels of depression (average PCL-5 score of 43.66) experienced clinically significant reductions in symptoms at the below time points following the retreat, with average PCL-5 scores along with percentage changes in symptoms relative to baseline and sample size (n) shown below:
The data presented here do not account for a number of post-retreat lifestyle factors, including therapeutic support and approach to self-care undertaken by clients once back at home. Some clients did not complete or have not reached all follow-up assessment time points. MycoMeditations is continually exploring ways to support the ongoing therapeutic treatment of its clients and always recommends full follow-up and integration procedures as well as continual, conventional mental health support and care in order to ensure the best long-term psychological outcomes.
Survey Set-Up Details
These longitudinal surveys assess the long-term outcomes of guests who attend psilocybin-assisted retreats offered by MycoMeditations in Jamaica.
MycoMeditations’ longitudinal surveys are not and do not attempt to constitute either an academic study or a registered clinical trial in their procedure, structure, or review process. However, insights drawn from this data convey a need for additional research into the mental health therapeutic benefits of psilocybin and points toward efficacy of treatment models outside of standard clinical and laboratory contexts. All data shared by MycoMeditations was analyzed and verified by a third-party academic partner.
This report shares the retreat outcomes in guests who joined us to overcome PTSD that contributed to our longitudinal surveys over the course of a year following their retreat.
MycoMeditations’ psilocybin-assisted retreat model led to clinically significant outcomes in the treatment of PTSD according to client surveys. These results also suggested long-term efficacy, with significant positive results remaining one year after the retreat experience.
All data represented here was collected between July 2021 and March 2024 with the consent of MycoMeditations clients.
